20 Questions About Parkinson’s Treatment: Medicines, DBS, New Therapies and Care in China

Treatment decisions in Parkinson’s disease change with the main symptoms, response to medication and the patient’s daily needs. These 20 questions help prepare a clinical discussion, understand the limits of treatment and organize a possible visit to China. Drug and technology information was checked through September 2026. The receiving institution must confirm individual suitability, the applicable Chinese access pathway and actual charges.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

No. Clinical assessment needs to identify bradykinesia and consider rest tremor, rigidity and other findings. Essential tremor, medication effects and other neurological conditions can also cause shaking, while some people with Parkinson’s do not begin with prominent tremor. Explain whether the movement is worse at rest or during an action, which side was affected first and whether walking or hand tasks have become slower. A brief video or a single symptom cannot establish the diagnosis. The specialist also needs the development of symptoms and the examination. MDS clinical diagnostic criteria
The absence of implanted equipment does not remove risk or establish cure. First identify the target, side and symptom being treated. A focal lesion cannot simply be turned back by changing a stimulation setting. A 2026 study of staged bilateral pallidothalamic-tract treatment reported persistent speech, gait and balance effects in some participants, making the additional benefit of the second side a careful decision. Do not transfer experience with bilateral treatment for a different condition to a proposed Parkinson’s procedure. Ask what will be followed afterward and which first-side outcomes could change any plan for further treatment. 2026 staged bilateral focused-ultrasound study
Fever with severe rigidity, sudden profound immobility, altered awareness, inability to take essential medication or rapid decline after stimulation interruption warrants prompt local emergency assessment. Infection, dehydration, medication interruption and withdrawal-related syndromes may require hospital care. New one-sided weakness, chest pain or breathing difficulty should not be attributed to Parkinson’s without assessment. A caregiver can bring the current prescription and device details to the emergency team. Once the acute situation is stabilized, communicate with the Chinese service about the longer-term plan. Waiting for a cross-border message response cannot replace timely local treatment. Guideline on akinetic crisis and withdrawal syndromes

Quick answer

Full guide

1. Does a shaking hand mean Parkinson’s disease?

No. Clinical assessment needs to identify bradykinesia and consider rest tremor, rigidity and other findings. Essential tremor, medication effects and other neurological conditions can also cause shaking, while some people with Parkinson’s do not begin with prominent tremor. Explain whether the movement is worse at rest or during an action, which side was affected first and whether walking or hand tasks have become slower. A brief video or a single symptom cannot establish the diagnosis. The specialist also needs the development of symptoms and the examination. MDS clinical diagnostic criteria

2. Must I obtain PET or a dopamine-transporter scan before visiting China?

The need depends on the diagnostic question. A scan should not be a universal entry requirement for every patient. The 2026 Chinese PET/MRI consensus discusses use in the assessment of parkinsonian syndromes within particular clinical circumstances. Submit existing reports and complete images first so that the receiving team can decide what is useful and whether further imaging would change management. An advanced imaging package does not replace examination by a neurologist, and it does not necessarily make a surgical decision quicker. Ask which uncertainty the proposed investigation is intended to resolve. Chinese PET/MRI consensus for parkinsonian syndromes

3. Does a positive genetic result mean my relatives will develop Parkinson’s?

Not necessarily. The report needs interpretation of pathogenic variants, risk-associated variants or variants of uncertain significance, together with penetrance and family context. Any result described casually as positive should not become a prediction that a relative will definitely become ill. Expert discussion of Parkinson’s genetic testing emphasizes appropriate selection and counseling. If the concern involves family planning, inherited risk or a specific research study, take the full report to the relevant professional. Do not assign a diagnosis to an unaffected relative from one line on the patient’s laboratory result. Expert discussion of genetic testing in Parkinson’s disease

4. When should treatment begin if symptoms are still mild?

Consider the effect on life, not only how recently the diagnosis was made. Difficulty dressing, typing, working or walking can justify discussion of expected benefit and adverse effects. Early-treatment guidance supports selection according to motor needs and cognitive or behavioral risks, rather than an identical first prescription for everyone. Describe the activities you most want to improve and mention driving, work requiring alertness and available assistance. This allows the prescriber to weigh the treatment against the demands of an ordinary day. The timing and pace of adjustment should then be agreed with the clinician. AAN guideline for early dopaminergic treatment

5. Does levodopa stop working after a fixed number of years?

Response can change, but fluctuations do not mean that every patient reaches a deadline after which levodopa becomes ineffective. The five-year LEAP follow-up compared earlier and delayed initiation of a specific low-dose strategy and did not detect a clear difference in the progression and motor-complication outcomes examined. It does not create an individual timetable for saving medication benefit by stopping treatment. If the effect becomes less predictable, show the clinician the daily pattern. Avoid enduring substantial functional difficulty or changing treatment independently based on a supposed fixed lifetime limit. Five-year LEAP follow-up

6. Does wearing off before the next dose mean sudden disease progression?

It may reflect end-of-dose wearing-off, but delivery, absorption, actual medication use and other factors also need consideration. Record when the dose was taken, when improvement began and when difficulty returned. Mention constipation, swallowing problems and relevant meals. Expert work on gastrointestinal barriers discusses how these issues can affect levodopa delivery; it does not establish that every patient needs gastrointestinal investigations or antibiotic treatment. The first task is to recognize the individual pattern. The prescriber can then decide whether a schedule, formulation or other part of management should change. Review of gastrointestinal barriers to levodopa delivery

7. Are twisting movements the same as worsening tremor?

Dyskinesia and tremor can both look like movement that is outside the patient’s control, but their implications differ. Describe whether the movement appears when benefit is strongest, when a dose begins to work or as its effect fades. Explain whether it interferes with walking, eating or sleep. The 2025 MDS review assesses treatment options for fluctuations, but an individual decision still needs the symptom burden and relevant risks. Reducing all medicines on your own may worsen mobility, while simply adding more may also be inappropriate. A safely recorded short video can help the clinician understand the movement. MDS evidence review on motor fluctuations

8. Should I report new shopping, gambling or sudden sleepiness after medication?

Yes. Some dopaminergic treatment can be associated with impulse-control problems, and longitudinal research links dopamine-agonist exposure with this risk. A patient may not fully recognize the change, so a caregiver’s observations can be important. Explain when the behavior began, its consequences and any preceding dose increase. Ask for a private discussion if the subject is difficult to raise in front of others. It should not simply be dismissed as a change in personality. Do not abruptly withdraw treatment independently; clinicians need to weigh medication changes against potential withdrawal effects. Study of dopamine agonists and impulse-control disorders

9. When is a DBS consultation worth considering?

If troublesome motor problems remain inadequately controlled with the current approach, ask the movement-disorder team whether specialist surgical assessment is appropriate. Medication response, cognition and psychiatric symptoms, general health, goals and continuing support all influence that judgment. The 2026 consensus distinguishes referral from operative eligibility and does not reduce the whole decision to a single screening score. During consultation, ask which symptoms the team expects to help and which may remain. Walking, speech and other difficulties do not all respond in the same way, so the proposed target should be connected to the patient’s actual priorities. 2026 DBS referral consensus

10. Can I stop medication and follow-up once DBS is implanted?

That outcome should not be promised in advance. Medication often needs adjustment alongside stimulation, with the aim of improving symptoms and treatment burden in daily life. The amount of reduction varies. Three-year randomized follow-up shows that movement benefit, quality of life and cognition do not necessarily change together. Before leaving the hospital, establish arrangements for programming, charging or battery management, fault assessment and support at home. Independently switching stimulation off or stopping medication can cause substantial deterioration. Implantation is one part of continuing care, rather than confirmation that every future symptom has been addressed. Three-year DBS follow-up

11. Is focused ultrasound more likely to cure Parkinson’s because it leaves no implant?

The absence of implanted equipment does not remove risk or establish cure. First identify the target, side and symptom being treated. A focal lesion cannot simply be turned back by changing a stimulation setting. A 2026 study of staged bilateral pallidothalamic-tract treatment reported persistent speech, gait and balance effects in some participants, making the additional benefit of the second side a careful decision. Do not transfer experience with bilateral treatment for a different condition to a proposed Parkinson’s procedure. Ask what will be followed afterward and which first-side outcomes could change any plan for further treatment. 2026 staged bilateral focused-ultrasound study

12. Is the cell treatment approved in Japan in 2026 an ordinary stem-cell infusion?

It is not the same intervention. Japan’s March 2026 conditional, time-limited approval for AMCHEPRY concerns a specified allogeneic iPS-derived dopaminergic neural progenitor-cell product and indication. It should not be generalized to cells from any source, intravenous administration or automatic routine availability in China. It also does not justify a guarantee of cure. If offered cell treatment, verify the exact product, route and procedure, regulatory or research status, subsequent monitoring and risks. A broad phrase such as stem-cell treatment is too imprecise to identify what evidence applies. AMED official information on the Japanese approval

13. Can I take a GLP-1 diabetes or weight-loss drug myself to slow Parkinson’s?

Do not start it for that purpose independently. The 2025 phase III exenatide paper reported a negative primary outcome, but The Lancet issued an Expression of Concern in June 2026, and that status must accompany discussion of the study. The notice is not evidence of a positive treatment effect either. Different GLP-1-related medicines and trials should not be treated as interchangeable, and an established diabetes indication does not demonstrate Parkinson’s benefit. If you already use such a medicine for another condition, tell both clinical teams and continue its management according to the relevant indication. Exenatide trial, 2026 Expression of Concern

14. Which recent medicine-safety update should I discuss at review?

In 2026 the FDA required warnings about vitamin B6 deficiency and associated seizures for the specified carbidopa/levodopa-containing products, with assessment and monitoring advice. Ask the clinician to check your exact combination, formulation, existing laboratory results and supplements and decide how to apply appropriate follow-up. This is not a reason for every patient to stop treatment suddenly, and more vitamin supplementation is not automatically better. Regulatory labeling is updated separately across countries. A US change should not be described as proof that every Chinese formulation has already undergone the same revision. FDA 2026 safety communication

15. If meals take longer and I cough while eating, is softer food enough?

Do not reduce the issue to one dietary suggestion. Swallowing, oral movement, nutrition and medication administration may all be involved. Describe coughing, weight changes and the part of a meal that becomes difficult. Consensus guidance supports clinical screening and instrumental assessment when indicated, followed by an individual plan. Do not crush every modified-release medicine independently, and do not assume that drinking without coughing on one occasion excludes a problem. Bring previous swallowing assessments and texture recommendations so that the receiving team can judge what has changed and what further assessment is needed. Consensus on diagnosis of dysphagia

16. Can I fly to China with longstanding disease or an implanted DBS system?

The decision depends on current symptoms, stability and help during the journey, rather than disease duration or an implant alone. Recent fainting, acute confusion, inability to take medication or recent intracranial surgery needs assessment by the treating clinician. CAA passenger guidance emphasizes preparation according to the condition and maintenance of medication schedules. Rules for licensing pilots should not be applied to ordinary passengers. With a device, follow the instructions for that particular system and check required assistance with the operating airline in advance. Confirm each segment when connections or different carriers are involved. CAA neurological guidance for passengers

17. Can an online DBS price serve as my entire budget?

Only estimates describing the same clinical plan, equipment, admission and follow-up can be meaningfully compared. NHSA’s neurological price-item explanation concerns standardized service items and local implementation; it does not set one total patient bill across China. Ask the hospital to identify equipment, surgery, anesthesia, investigations, programming and potentially separate charges. Confirm your own policy coverage with the payer. A brain-computer-interface technical fee, reimbursement code or another patient’s insurance result does not establish your eventual out-of-pocket amount. An estimate should also explain which items remain dependent on clinical assessment. NHSA explanation of neurological service price items

18. What is the most useful question when choosing a hospital?

Ask who will handle diagnosis and medication, who participates in procedural assessment and who will manage equipment or complications after you return home. An official department description can identify an entry point: Tiantan’s functional-neurosurgery page includes movement disorders, for example. It cannot guarantee an individual outcome, appointment or international service. Ask what alternative is offered if a proposed treatment is unsuitable, and check language support, record submission and financial communication. Clear explanations of treatment limits provide more useful information than a promise that every symptom will improve. Tiantan functional-neurosurgery department

19. Is video contact with the Chinese doctor enough after I go home?

Video can help discuss prescriptions, observe some movements and explain reports, but it cannot provide every examination or emergency intervention. Randomized research supports feasibility and reduced travel burden without proving superior outcomes across all aspects of care. Arrange a local responsible clinician and transfer the original reports, current medication list and device records. Establish which reviews must occur in person. Every remote contact should have a specific question and an agreed next step. An instruction to stay in touch is not a substitute for a follow-up plan the household can actually carry out. Randomized study of virtual Parkinson’s visits

20. Which changes should not wait for travel or the next routine appointment?

Fever with severe rigidity, sudden profound immobility, altered awareness, inability to take essential medication or rapid decline after stimulation interruption warrants prompt local emergency assessment. Infection, dehydration, medication interruption and withdrawal-related syndromes may require hospital care. New one-sided weakness, chest pain or breathing difficulty should not be attributed to Parkinson’s without assessment. A caregiver can bring the current prescription and device details to the emergency team. Once the acute situation is stabilized, communicate with the Chinese service about the longer-term plan. Waiting for a cross-border message response cannot replace timely local treatment. Guideline on akinetic crisis and withdrawal syndromes